Country: Amerika Syarikat
Bahasa: Inggeris
Sumber: NLM (National Library of Medicine)
BUTALBITAL (UNII: KHS0AZ4JVK) (BUTALBITAL - UNII:KHS0AZ4JVK), ACETAMINOPHEN (UNII: 362O9ITL9D) (ACETAMINOPHEN - UNII:362O9ITL9D)
Granules Pharmaceuticals Inc.
ORAL
PRESCRIPTION DRUG
Butalbital and acetaminophen capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. This product is contraindicated under the following conditions: • Hypersensitivity or intolerance to any component of this product. • Patients with porphyria. Abuse and Dependence Butalbital Barbiturates may be habit-forming: Tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occu
Each butalbital and acetaminophen capsule contains butalbital 50 mg and acetaminophen 300 mg. Capsules are blue opaque cap printed with "GPI (over) 50/300mg" and blue opaque body printed with "054" contains white to off-white blend and are available in bottles of 100’s and 500’s count. Bottles of 100 NDC 70010-054-01 Bottles of 500 NDC 70010-054-05 Store at 20°C to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight container as defined in the USP. Rx Only Manufactured By: Granules Pharmaceuticals Inc., Chantilly, VA 20151 Rev. 05/2019
Abbreviated New Drug Application
BUTALBITAL AND ACETAMINOPHEN- BUTALBITAL AND ACETAMINOPHEN CAPSULE GRANULES PHARMACEUTICALS INC. ---------- BUTALBITAL AND ACETAMINOPHEN – BUTALBITAL AND ACETAMINOPHEN CAPSULE GRANULES PHARMACEUTICALS INC. BOXED WARNING HEPATOTOXICITY Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen containing product. DESCRIPTION Each capsule for oral administration contains butalbital USP, 50 mg and acetaminophen USP, 300 mg. In addition, each capsule also contains the following inactive ingredients: crospovidone, FD&C Blue #1, FD&C Red #3, gelatin, microcrystalline cellulose, povidone, pregelatinized starch, sodium lauryl sulphate, stearic acid, talc and titanium dioxide. In addition, capsule printing ink contains ammonium hydroxide, black iron oxide, propylene glycol and shellac glaze. Butalbital (5-allyl-5-isobutylbarbituric acid), a slightly bitter, white, odorless, crystalline powder, is a short to intermediate-acting barbiturate. It has the following structural formula: C H N O MW 224.26 Acetaminophen (4’-hydroxyacetanilide), a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula: 11 16 2 3 C H NO MW 151.16 CLINICAL PHARMACOLOGY This combination drug product is intended as a treatment for tension headache. It consists of a fixed combination of butalbital and acetaminophen. The role each component plays in the relief of the complex of symptoms known as tension headache is incompletely understood. PHARMACOKINETICS The behavior of the individual components is described below. Butalbital Butalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body. Barbiturates in general may appear in breast milk and readily cross the placental ba Baca dokumen lengkap